09:07 AM EDT, 06/30/2025 (MT Newswires) -- Launch One Acquisition's ( LPAA ) merger target Minovia Therapeutics said Monday it has been granted US Food and Drug Administration fast-track designation for its lead investigational compound MNV-201, which is intended as a treatment for Pearson Syndrome.

The company said the FDA also granted the drug candidate rare pediatric disease designation. The drug candidate is in phase 2 clinical trials for the treatment of the disease, the company said.

Launch One, a blank-check company, is expected to close its business combination with Minovia in late 2025, the company said.

Pearson Syndrome is a rare genetic disorder that leads to bone marrow failure, metabolic crises, and organ dysfunction.